Alector ( ALEC ) Q2 Revenue Falls 48%
Alector ( NASDAQ:ALEC ) , a biotechnology company focused on developing therapies for neurodegenerative diseases, reported its results for the second quarter of 2025 on August 7, 2025. The most important news from this earnings release is a sharp outperformance compared to analyst expectations, ...
Alector ( ALEC ) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
This Texas Instruments Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - MARA Holdings ( NASDAQ:MARA ) , Alector ( NASDAQ:ALEC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Matthew Boss upgraded the rating for NIKE, Inc.
Alector Provides Executive Leadership Update - Alector ( NASDAQ:ALEC )
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc.
Alector Provides Executive Leadership Update
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc. ( Nasdaq: ALEC ) , a late-stage clinical biotechnology company focused on developing ...
Lexicon Pharmaceuticals ( LXRX ) Reports Q1 Loss, Lags Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 30% and 23.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics ( IOVA ) Reports Q1 Loss, Misses Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -44% and 38.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
AUSTIN, Texas, April 21, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc. ( NASDAQ: SAVA, "Cassava", the "Company" ) , a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system ( CNS ) disorders such as ...
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development - Cassava Sciences ( NASDAQ:SAVA )
AUSTIN, Texas, April 21, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc.
Alector Provides Executive Leadership Update - Alector ( NASDAQ:ALEC )
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc.
Alector Provides Executive Leadership Update
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer ...
Alector ( ALEC ) Reports Q4 Loss, Tops Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of 96.88% and 220.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for ...
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts - Alector ( NASDAQ:ALEC )
Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program. Alector recently released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease ( AD ) .
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
Crude Oil Moves Lower; Dick's Sporting Goods Earnings Top Views - Alector ( NASDAQ:ALEC ) , Dick's Sporting Goods ( NYSE:DKS )
U.S. stocks traded mostly higher toward the end of trading, with the S&P 500 gaining around 0.5% on Tuesday. The Dow traded up 0.05% to 44,759.66 while the NASDAQ rose 0.59% to 19,166.93. The S&P 500 also rose, gaining, 0.47% to 6,015.37. Utilities shares jumped by 1.1% on Tuesday.
Nasdaq Rises 100 Points; Abercrombie & Fitch Shares Fall After Q3 Results - Alector ( NASDAQ:ALEC ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded down 0.26% to 44,621.76 while the NASDAQ rose 0.52% to 19,154.38. The S&P 500 also rose, gaining, 0.37% to 6,009.72. Utilities shares jumped by 1.1% on Tuesday.
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce - Alector ( NASDAQ:ALEC )
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease ( AD ) .
US Stocks Mixed; Best Buy Posts Downbeat Earnings - Alector ( NASDAQ:ALEC ) , Best Buy Co ( NYSE:BBY )
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.47% to 44,528.35 while the NASDAQ rose 0.48% to 19,149.12. The S&P 500 also rose, gaining, 0.22% to 6,000.53.
Leslie's Posts Weak Results, Joins Zoom Video And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Alector ( NASDAQ:ALEC ) , Agora ( NASDAQ:API )
U.S. stock futures were slightly higher this morning, with the Nasdaq futures gaining around 0.1% on Tuesday. Shares of Leslie's, Inc. LESL fell sharply in today's pre-market trading after the company reported worse-than-expected fourth-quarter adjusted EPS and sales.
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket - Alector ( NASDAQ:ALEC ) , Channel Therapeutics ( AMEX:CHRO )
Shares of Poseida Therapeutics, Inc. PSTX rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal. Poseida Therapeutics shares jumped 218.8% to $9.12 in the pre-market trading session. Here are some other stocks moving in pre-market ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update - Alector ( NASDAQ:ALEC )
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc.
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital - Alector ( NASDAQ:ALEC ) , Hercules Capital ( NYSE:HTGC )
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ALEC, a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. HTGC for up to $50 million.
Alector ( ALEC ) Reports Q3 Loss, Misses Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of 18.87% and 6.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences ( DTIL ) Surges 6.1%: Is This an Indication of Further Gains?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias ( ISFTD 2024 ) - Alector ( NASDAQ:ALEC ) , GSK ( NYSE:GSK )
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation ( FTD-GRN ) --
Ascendis Pharma ( ASND ) Moves 17.1% Higher: Will This Strength Last?
Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Alector to Participate in Upcoming Healthcare Conferences - Alector ( NASDAQ:ALEC )
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ALEC, a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Thursday, September 5, 2024, at 7:45 a.m.
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ( Nasdaq: ALEC ) , a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: ...
Alector ( ALEC ) Reports Q2 Loss, Lags Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of 18.37% and 5.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences ( AKYA ) Reports Q2 Loss, Misses Revenue Estimates
Akoya (AKYA) delivered earnings and revenue surprises of 0% and 1.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 ( AAIC® )
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease ( AD ) -- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that ...
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 ( AAIC® ) - Alector ( NASDAQ:ALEC ) , AbbVie ( NYSE:ABBV )
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease ( AD ) --
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® ( AAIC® ) 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ( Nasdaq: ALEC ) , a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association ...
Prothena ( PRTA ) Moves 9.3% Higher: Will This Strength Last?
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - Alector ( NASDAQ:ALEC )
SOUTH SAN FRANCISCO, Calif., June 20, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ALEC, a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C.
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Perion Network ( NASDAQ:PERI )
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Monday. Shares of Perion Network Ltd. PERI fell sharply in today's pre-market trading after the company lowered its revenue forecast.
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation ...
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform - Alector ( NASDAQ:ALEC )
SOUTH SAN FRANSISCO, Calif., June 10, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc.
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., May 09, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ( Nasdaq: ALEC ) , a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: ...
Alector ( ALEC ) Reports Q1 Loss, Tops Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Alector ( ALEC ) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?
Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...
Alector to Participate in Upcoming Healthcare Conferences - Alector ( NASDAQ:ALEC )
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Alector, Inc. ALEC, a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Tuesday, March 5, 2024, at 10:30 a.m.
Earnings Preview: Alector ( ALEC ) Q4 Earnings Expected to Decline
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally ...
Strength Seen in Alector ( ALEC ) : Can Its 6.0% Jump Turn into More Strength?
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation ( FTD-GRN )
-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the treatment of ...
AbbVie ( ABBV ) Q4 2023 Earnings Call Transcript
ABBV earnings call for the period ending December 31, 2023.
Alector ( ALEC ) Upgraded to Strong Buy: Here's What You Should Know
Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
